prognostic significance of molecular mrd in npm1-mutated aml treated with venetoclax-based therapy
Published 11 months ago • 128 plays • Length 2:03Download video MP4
Download video MP3
Similar videos
-
1:13
molecular mrd as a prognostic marker for aml patients with mutated cebpa
-
1:19
the prognostic value of mrd in cll
-
3:35
minimal residual disease (mrd) as a prognostic factor for acute myeloid leukemia (aml)
-
2:41
assessing the prognostic value of ngs-based mrd in adults with all undergoing sct
-
1:36
the importance of mrd as a prognostic tool in multiple myeloma
-
4:22
the role of mrd in aml
-
5:38
the molecular and clinical classifications of mds
-
3:03
prognostic importance of mrd: results of tourmaline-mm4 trial for ndmm
-
2:21
mezigdomide: a novel celmod showing promise in the treatment of r/r myeloma
-
13:47
latest news in myeloma: mrd, bites, and car t-cells
-
2:09
mrd in multiple myeloma: prognosis, a clinical trial endpoint, and guiding treatment decisions
-
5:18
the value of mrd as a prognostic tool in myeloma
-
3:22
the main prognostic factors and why minimal residual disease is becoming crucial in multiple myeloma
-
1:32
the importance of cytogenetics and molecular profiling for accurate aml/mds diagnosis
-
3:27
mrd negativity using deep sequencing is a major prognostic factor in myeloma
-
2:18
prognostic factors and mutations in mds
-
1:36
identification of high-risk disease using molecular profiling by mymap
-
2:03
updated fda mrd guidelines for hematological malignancies
-
2:18
molecular profiling and risk classification of patients with mpns and splanchnic vein thromboses
-
3:23
molecular characteristics associated with increased risk of disease progression in smm
-
3:31
relevance of the ipss-r during sct in patients with mds in the molecular classification era
-
4:02
the diagnostic and prognostic value of mass spectrometry in multiple myeloma